Progyny, Inc. cash flow to debt ratio of 758.10% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Progyny, Inc.'s free cash flow has increased 10.41% from $173.70M last year to $191.78M, signaling increasing performance

Progyny, Inc.'s debt to equity ratio is 0.06, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Progyny, Inc.'s debt has increased relative to shareholder equity from 0.05 last year to 0.06 today, signaling weakened financials

Progyny, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Progyny, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Progyny, Inc.'s profit margin has increased (12.45%) in the last year from 4.66% to 5.23%, signaling increasing performance

Progyny, Inc.'s short-term assets of $551.77M exceed its short-term liabilities of $202.39M

Progyny, Inc.'s return on assets of 9.69% is higher than the 5.00% threshold, indicating efficient asset utilization

Progyny, Inc.'s return on equity of 13.34%, is lower than 15.00%, indicating bad performance

Progyny, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Progyny, Inc. had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings

Progyny, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Progyny, Inc. has a free cash flow yield of 7.57%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Progyny, Inc.'s yearly earnings has increased 7.70% since last year from $54.34M to $58.52M, signaling increasing performance

Progyny, Inc.'s yearly revenue has increased 10.40% since last year from $1.17G to $1.29G, signaling increasing performance

ROIC 13.23% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Progyny, Inc.'s 3-year revenue CAGR of 17.87% is positive, indicating growing revenue over the past 3 years

Progyny, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Progyny, Inc. had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity

Progyny, Inc. is undervalued relative to its fair value price of 42.65 based on Discounted Cash Flow model

Progyny, Inc. has an earnings yield of 2.58%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Progyny, Inc. is overvalued relative to its fair value price of 9.66 based on EBITDA multiple model

Progyny, Inc. has an EV/EBITDA ratio of 24.41x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Progyny, Inc. is overvalued relative to its fair value price of 17.56 based on Earnings Fair Value model

Progyny, Inc. has a PEG-ratio over 1 which is considered overvalued

Progyny, Inc. has a price-to-book ratio of 5.96x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Progyny, Inc. has a price-to-sales ratio of 2.03x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue